Table 2 The relationship between clinical characteristics and overall survival in 224 patients: Cox’s regression analysis
Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
P value | Hazard ratio | 95% CI | P value | |||
Age | 0.013 | 0.988 | 0.975–1.002 | 0.084 | ||
Sex | 0.020 | 2.424 | 1.139–5.156 | 0.022 | ||
HBV DNA (log 10 IU/mL) | 0.602 | – | – | – | ||
ALT | 0.607 | – | – | – | ||
TNM stage (early:advanced) | <0.001 | 2.031 | 1.410–2.925 | <0.001 | ||
Cycles of TACE | 0.346 | – | – | – | ||
AST | <0.001 | 1.001 | 0.998–1.005 | 0.496 | ||
ALB | 0.043 | 0.950 | 0.913–0.988 | 0.010 | ||
TBIL | 0.028 | 1.007 | 0.986–1.029 | 0.511 | ||
AFP | <0.001 | 1.400 | 0.979–2.003 | 0.066 | ||
APTT | 0.259 | – | – | – | ||
Antiviral treatment | 0.044 | 0.635 | 0.454–0.888 | 0.008 | ||
Local ablation | <0.001 | 0.241 | 0.133–0.436 | <0.001 | ||
Resection | <0.001 | 0.298 | 0.148–0.599 | 0.001 | ||
HBeAg | 0.977 | – | – | – | ||
PT | 0.746 | – | – | – | ||
Sorafenib therapy | 0.825 | – | – | – | ||
Chemotherapeutic agents (epirubicin only:>2 agents) | 0.798 | – | – | – | ||